Plasma tissue factor pathway inhibitor and tissue factor antigen levels after administration of heparin in patients with angina pectoris

Thrombosis Research

Volumn 93, Issue 1, 1999, Pages 17-25

  Soejima, Hirofumi ^a   Ogawa, Hisao ^a   Yasue, Hirofumi ^a   Nishiyama, Koichi ^a   Kaikita, Koichi ^a   Misumi, Kenji ^a   Takazoe, Keiji ^a   Kugiyama, Kiyotaka ^a   Tsuji, Ichiro ^b   Kumeda, Kousuke ^b   Nakamura, Shin ^c  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b KAKETSUKEN   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

ANTIGEN; HEPARIN; PROTHROMBIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AGED; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HEART CATHETERIZATION; HUMAN; HYPERCOAGULABILITY; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; THORAX PAIN; THROMBOSIS;

ANGINA PECTORIS; ANTICOAGULANTS; ANTIGENS; FEMALE; HEPARIN; HUMANS; LINEAR MODELS; LIPOPROTEINS; MALE; MIDDLE AGED; THROMBOPLASTIN;

EID: 0032928882     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(98)00147-9     Document Type: Article

References (37)

1. Nemerson Y. Tissue factor and hemostasis. Blood. 71:1988;1-8.
2. Edgington T.S., Mackman N., Brand K., Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost. 66:1991;67-79.
3. Carson S.D., Brozna J.P. The role of tissue factor in the production of thrombin. Blood Coagul Fibrinolysis. 4:1993;281-292.
4. Annex B.H., Denning S.M., Channon K.M., Sketch M.H., Stack R.S., Morrissey J.H., Peters K.G. Differential expression of tissue factor protein in atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation. 91:1995;619-622.
5. Kaikita K., Ogawa H., Yasue H., Takeya M., Takahashi K., Saito T., Hayasaki K., Horiuchi K., Takizawa A., Kamikubo Y., Nakamura S. Tissue factor expression on macrophages in coronary plaques in patients with unstable angina. Arterioscler Thromb Vasc Biol. 17:1997;2232-2237.
6. Leatham E.W., Bath P.M.W., Tooze J.A., Camm A.J. Increased monocyte tissue factor expression in coronary disease. Br Heart J. 73:1995;10-13.
7. Soejima H., Ogawa H., Yasue H., Suefuji H., Kaikita K., Tsuji I., Kumeda K., Aoyama N. Effects of enalapril on tissue factor in patients with uncomplicated acute myocardial infarction. Am J Cardiol. 78:1996;336-340.
8. Suefuji H., Ogawa H., Yasue H., Kaikita K., Soejima H., Motoyama T., Mizuno Y., Oshima S., Saito T., Tsuji I., Kumeda K., Kamikubo Y., Nakamura S. Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J. 134:1997;253-259.
9. Misumi K., Ogawa H., Yasue H., Soejima H., Suefuji H., Nishiyama K., Takazoe K., Kugiyama K., Tsuji I., Kumeda K., Nakamura S. Comparison of plasma tissue factor levels in unstable and stable angina pectoris. Am J Cardiol. 81:1998;22-26.
10. Rao L.V.M., Rapaport S.I. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood. 69:1987;645-651.
11. Wun T.C., Kretzmer K.K., Girard T.J., Miletich J.P., Broze G.J. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem. 263:1988;6001-6004.
12. Broze G.J., Warren L.A., Novotny W.F., Higuchi D.A., Hirard J.J., Miletich J.P. The lipoprotein-associated coagulation inhibitor that inhibits the factor VIIa-tissue factor complex, also inhibits factor Xa. Insight into its possible mechanism of action Blood. 71:1988;335-343.
13. Girard J.J., Warren L.A., Novotny W.F., Likert K.M., Brown S.G., Miletich J.P., Broze G.J. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature. 338:1989;518-520.
14. Baja M.S., Kuppuswamy M.N., Saito H., Spitzer S.D., Baja S.P. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor. evidence that endothelium is the principal site of its synthesis Proc Natl Acad Sci USA. 87:1990;8869-8873.
15. Enjyoji K., Emi M., Mukai T., Kato H. cDNA cloning and expression of rat tissue factor pathway inhibitor (TFPI). J Biochem. 111:1992;681-687.
16. Sandset P.M., Abildgaad U., Larsen M.L. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res. 50:1988;803-813.
17. Novotny W.F., Palmier M., Wun T.C., Broze G.J., Miletich J.P. Purification and properties of heparin releasable lipoprotein associated inhibitor. Blood. 78:1991;394-400.
18. Lindahl A.K., Abildgaard U., Stokke G. Extrinsic pathway inhibitor after heparin injection. Increased response in cancer patients Thromb Res. 59:1990;651-656.
19. Abumiya T., Enjyoji K., Kokawa T., Kamikubo Y., Kato H. An anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form of TFPI but not lipoprotein-associated forms in Plasma. J Biochem. 118:1995;178-182.
20. Nishiyama K., Ogawa H., Yasue H., Soejima H., Misumi K., Kugiyama K., Tsuji I., Kumeda K. Heparin-releasable endothelial cell-associated tissue factor pathway inhibitor (TFPI) is increased in the coronary circulation after coronary spasm in patients with coronary spastic angina. Thromb Res. 89:1998;137-146.
21. Misumi K., Ogawa H., Yasue H., Soejima H., Hisakazu S., Nishiyama K., Takazoe K., Kugiyama K., Tsuji I., Kumeda K. Circadian variation in plasma levels of free-form tissue factor pathway inhibitor antigen in patients with coronary spastic angina. Jpn Circ J. 62:1998;419-424.
22. Bauer K.A., Rosenberg R.D. The pathophysiology of the prethrombotic state in humans. Insights gained from studies using markers of the hemostatic system activation Blood. 70:1987;343-350.
23. Lau H.K., Rosenberg J.S., Beeler D.L., Rosenberg R.D. The isolation and characterization of a specific antibody population directed against the prothrombin activation fragments F2 and prothrombin fragment 1+2. J Biol Chem. 254:1979;8751-8761.
24. Teien A.N., Lie M. Evaluation of an amidolytic heparin assay method. Increased sensitivity by adding purified antithrombin III Thromb Res. 10:1977;399-410.
25. Teien A.N., Abildgaard U., Höök M., Lindahl U. Anticoagulant activity of heparin. Assay of bovine, human and porcine preparations by amidolytic and clotting methods Thromb Res. 11:1997;107-117.
26. Kamei S., Kamikubo Y., Hamuro T., Fujimoto H., Ishihara M., Yonemura H., Miyamoto S., Funatsu A., Enjyoji K., Abumiya T., Miyata T., Kato H. Amino acid sequence and inhibitory activity of rhesus monkey tissue factor pathway inhibitor (TFPI). Comparison with human TFPI J Biochem. 115:1994;708-714.
27. Nakamura S., Goto A., Takemoto S., Mizuguti J., Funatsu A. Monoclonal antiboddies to human tissue factor. Thromb Haemost. 65:1991;1216.
28. Nakamura S., Kamikubo Y., Okajima K., Asakura H., Nakamura K. Plasma tissue factor. Its sensitive assay and characterization Thromb Haemost. 69:1993;744.
29. Pelzer H., Schwarz A., Stüber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost. 65:1991;153-159.
30. The RISC Group Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 336:1990;827-830.
31. The SCATI Group Randmized controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. Lancet. 2:1989;182-186.
32. Kienast J., Thompson S.G., Raskino C., Pelzer H., Fechtrup C., Ostermann H., Van de Loo J. Prothrombin activation fragment 1+2 and thrombin antithrombin III complexes in patients with angina pectoris. Relation to the presence and severity of coronary atherosclerosis Thromb Haemost. 70:1993;550-553.
33. Lindahl A.K., Jacobsen P.B., Sandset P.M., Abildgaard U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. Blood Coagulation Fibrinol. 2:1991;713-721.
34. Moor E., Hamsten A., Karpe F., Båvenholm P., Blombäch M., Silveira A. Relationship of tissue factor pathway inhibitor activity to plasma lipoproteins and myocardial infarction at a young age. Thromb Haemost. 71:1994;707-712.
35. Kokawa T., Enjyoji K., Kumeda K., Kamikubo Y., Harada-shiba M., Koh H., Tsushima M., Yamamoto A., Kato H. Measurement of the free form of TFPI antigen in hyperlipidemia. Relationship between free and endothelial cell-associated forms of TFPI Arterioscler Thromb Vasc Biol. 16:1996;802-808.
36. Lupu C., Lupu F., Dennehy U., Kakkar V.V., Scully M.F. Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture. Arterioscler Thromb Vasc Biol. 15:1995;2055-2062.
37. Abendschein D.R., Meng Y.Y., Torr-Brown S., Sobel B.E. Maintenance of coronary patency after fibrinolysis with tissue factor pathway inhibitor. Circulation. 92:1995;944-949.